SEARCH

SEARCH BY CITATION

References

  • 1
    Brunetto MR, Stemler M, Schodel F, Will H, Ottobrelli A, Rizzetto M, Verme G, et al. Identification of HBV variants which cannot produce precore derived HBeAg and may be responsible for severe hepatitis. Ital J Gastroenterol 1989; 21:151154.
  • 2
    Carman WF, Jacyna MR, Hadziyannis S, Karayiannis P, McGarvey MJ, Makris A, Thomas HC. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989; 2:588591.
  • 3
    Hadziyannis SJ, Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2001; 34:617624.
  • 4
    Brunetto MR, Oliveri F, Coco B, Leandro G, Colombatto P, Monti Gorin J, Bonino F. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol 2002; 36:263270.
  • 5
    Brunetto MR, Oliveri F, Rocca G, Criscuolo D, Chiaberge E, Capalbo M, David E, et al. Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen. Hepatology 1989; 10:198202.
  • 6
    Papatheodoridis GV, Manesis E, Hadziyannis SJ. The long-term outcome of interferon-α treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol 2001; 34:306313.
  • 7
    Marco V, Lo Iacono O, Cammà C, Vaccaro A, Giunta M, Martorana G, Fuschi P, et al. The long-term course of chronic hepatitis B. Hepatology 1999; 30:257264.
  • 8
    Fattovich G, Giustina G, Christensen E, Pantalena M, Zagni I, Realdi G, Schalm SW, et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. Gut 2000; 46:420426.
  • 9
    Lok ASF, McMahon BJ. Chronic hepatitis B. Hepatology 2001; 34:12251241.
  • 10
    Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, Hsiao CK, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002; 347:168174.
  • 11
    Hadziyannis S, Bramou T, Makris A, Moussoulis G, Zignego L, Papaioannou C. Interferon alpha-2b treatment for HBeAg negative/serum HBV-DNA positive chronic active hepatitis type B. J Hepatol 1990; 11(Suppl 1):S133S136.
  • 12
    Fattovich G, Farci P, Rugge M, Brollo L, Mandas A, Pontisso P, Giustina G, et al. A randomized controlled trial of lymphoblastoid interferon-alpha in patients with chronic hepatitis B lacking HBeAg. Hepatology 1992; 15:584589.
  • 13
    Pastore G, Santantonio T, Milella M, Monno L, Mariano N, Moschetta R, Pollice L. Anti-HBe-positive chronic hepatitis B with HBV-DNA in the serum: response to a 6-month course of lymphoblastoid interferon. J Hepatol 1992; 14:221225.
  • 14
    Manesis EK, Hadziyannis SJ. Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology 2001; 121:101109.
  • 15
    Lampertico P,Del Ninno E, Manzin A, Donato MF, Rumi MG, Lunghi G, Morabito A, et al. A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis virus DNA without hepatitits B e antigen in serum. Hepatology 1997; 26:16211625.
  • 16
    Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, Goldin RD, Hawley S, et al. Efficacy of lamivudine in patients with hepatitis B e Antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology 1999; 29:889896.
  • 17
    Hadziyannis SJ, Papatheodoridis GV, Dimou E, Laras A, Papaioannou C. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000; 32:847851.
  • 18
    Brunetto MR, Torrani Cerenzia M, Oliveri F, Piantino P, Randone A, Calvo PL, Manzini P, et al. Monitoring the natural course and response to therapy of chronic hepatitis B with an automated semi-quantitative assay for IgM anti-HBc. J Hepatol 1993; 19:431436.
  • 19
    Scotto J, Hadchouel M, Hery C, Yvart J, Tiollais P, Brechot C. Detection of hepatitis B virus DNA in serum by a simple spot hybridization technique: comparison with results for other viral markers. Hepatology 1983; 3:279284.
  • 20
    Stuyver L, Wyseur A, van Arnhem W, Hernandez F, Maertens G. Second-generation line probe assay for hepatitis C virus genotypes. J Clin Microbiol 1996; 34:22592266.
  • 21
    Stuyver L, Van Geyt C, De Gendt S, Van Reybroeck G, Zoulim F, Leroux-Roels G, Rossau R. Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy. J Clin Microbiol 2000; 38:702707.
  • 22
    Ishak K, Baptista A, Bianchi L, Callea F,De Groote J, Gudat F, Denk H, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22:696699.
  • 23
    Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. J Hepatol 2001; 35:421430.
  • 24
    Schoenfeld D. Partial residuals for the proportional hazards regression model. Biometrika 1982; 69:239241.
  • 25
    Oliveri F, Santantonio T, Bellati G, Colombatto P, Colloredo Mels G, Carriero L, Dastoli G, et al. Long-term response to therapy of chronic anti-HBe-positive hepatitis B is poor independent of type and schedule of interferon. Am J Gastroenterol 1999; 94:13661372.
  • 26
    Lobello S, Lorenzoni U, Vian A, Floreani A, Brunetto MR, Chiaramonte M. Interferon treatment in hepatitis B surface antigen-positive hepatitis B e antibody-positive chronic hepatitis B: role of hepatitis B core antibody Ig titre in patient selection and treatment monitoring. J Viral Hepat 1998; 5:6166.
  • 27
    Erhardt A, Reineke U, Blondin D, Gerlich WH, Adams O, Heintges T, Niederau C, et al. Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B. Hepatology 2000; 31:716725.
  • 28
    Cammà C, Giunta M, Andreone P, Craxìgı A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol 2001; 34:593602.
  • 29
    Brechot C, Gozuacik D, Murakami Y, Paterlini-Brechot P. Molecular bases for the development of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). Semin Cancer Biol 2000; 10:211231.